09/07/2026 CSPC’s B7-H3 ADC SYS6043 secures Breakthrough Therapy Designation in China for platinum-resistant Ovarian cancer CSPC’s B7-H3 ADC SYS6043 secures Breakthrough Therapy Designation in China for platinum-resistant Ovarian cancer (Ref) CSPC Pharmaceutical's antibody-drug conjugate (ADC) SYS6043, targeting B7-H3, has received Breakthrough Therapy Designation from China’s NMPA for platinum-resistant ovarian cancer, primary peritoneal carcinoma, and fallopian tube cancer